ADMINISTRATION OF ROSIGLITAZONE IN PATIENTS WITH SLEEP APNEA

睡眠呼吸暂停患者服用罗格列酮

• 批准号: 7378493
• 负责人: ALEXANDROS N VGONTZAS
• 金额: $ 10.07万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378493
• 关键词: ADMINISTRATION; ROSIGLITAZONE; PATIENTS; SLEEP; APNEA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary hypothesis of this study is that insulin resistance/visceral obesity is a pathogenetic factor in obstructive sleep apnea and is a primary determinant of its clinical severity.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的基本假设是胰岛素抵抗/内脏肥胖是阻塞性睡眠呼吸暂停的致病因素，也是其临床严重性的主要决定因素。